cd19 specific chimeric antigen receptor t cell
Large B-Cell Lymphoma
Explore 71 assets in Large B-Cell Lymphoma →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Pell Bio-Med Technology Co., Ltd.
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05326243CT.gov Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd19 specific chimeric antigen receptor t cell (this asset) | Pell Bio-Med Technology Co., Ltd. | P1/2 | CC · 43 |
| Axicabtagene Ciloleucel | Zhejiang Cancer Hospital | P4 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
| Fludarabine | M.D. Anderson Cancer Center | P4 | BB |
| Etoposide | University of California, Davis | P2/3 | BB |
| Prednisone | Ruijin Hospital | P3 | BB |
| Adriamycin | Ruijin Hospital | P3 | BB |
| Lenalidomide | Ruijin Hospital | P3 | B |
| Rituximab | Ruijin Hospital | P3 | B |
+41 more in the Large B-Cell Lymphoma cohort
Other indications for cd19 specific chimeric antigen receptor t cell
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Follicular Lymphoma | — | P1/2 | CCC · 48 |
| Primary Mediastinal Large B-Cell Lymphoma | — | P1/2 | CC · 45 |
| Diffuse Large B-Cell Lymphoma | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cd19 specific chimeric antigen receptor t cell in Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd19-specific-chimeric-antigen-receptor-t-cell-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →